JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The H4-Index of JPAD-Journal of Prevention of Alzheimers Disease is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Herpes zoster and dementia : more evidences for a causal link639
Gene and genetic therapies in Alzheimer’s disease and other dementias147
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations139
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217121
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort104
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats93
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France89
Lecanemab over a two-year duration: Key insights from a regional specialty medical center84
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease74
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease72
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation64
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.62
Long-term fasting insulin variability and cognitive function: Insights from the CARDIA study57
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use52
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings48
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice44
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease44
Prevention of dementia using mobile phone applications (PRODEMOS) – a health-economic cost-utility analysis in people aged 55–75 years with low socio-economic status42
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data42
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status41
Structural social factors modify the association between Alzheimer’s pathology and cognitive function41
Introduction to the Special Issue on the A4 Study40
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration39
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment37
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese35
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias34
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review34
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease33
Informal care for people with dementia in Europe32
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population31
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system31
Content31
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test31
0.56471610069275